Checks every doctor's license against state records to build a verified physician network that drug companies can legally advertise to.
At a glance
- Depends onMidstream position: 4 outgoing, 6 incoming connections
- Scale
Checks every doctor's license against state records to build a verified physician network that drug companies can legally advertise to.
Doximity checks every doctor on its platform against state medical board records and the National Provider Identifier database — a manual process run separately across all 50 states because each jurisdiction uses different documentation formats — to produce a verified directory that covers over 80% of U.S. physicians. That verified identity layer is what makes the network HIPAA-eligible, which is what allows doctors to route patient information through the platform's encrypted fax, telehealth, and on-call scheduling tools, and which is also what pharmaceutical advertisers are paying for when they target a specific specialty for a drug launch. Because no other network has run the same 50-state credentialing process at scale, a competitor cannot simply buy its way to equivalent coverage — the verification work takes years that capital alone cannot compress. The whole structure rests on continued access to state licensing databases, so if a significant number of boards restrict third-party queries, the credentialing pipeline loses its source data, the verified audience shrinks, and the specialty-targeting guarantee that underpins advertiser spending disappears with it.
How does this company make money?
The main source of revenue is advertising fees paid by pharmaceutical and medical device companies to run targeted campaigns aimed at verified doctors — for example, promoting a newly approved drug to cardiologists or recruiting oncologists for a clinical trial. The company also charges subscription fees to doctors and health systems that use its premium tools, including secure messaging, Amion scheduling, and Dialer telehealth.
What makes this company hard to replace?
Doctors who use the platform have built it into their daily work — encrypted faxing, Amion on-call scheduling, and Dialer telehealth are all woven into how they communicate and see patients. Replacing those tools means retraining staff and rebuilding workflows. Pharmaceutical advertisers face a different friction: no other network can prove that its physician profiles are currently licensed and practicing, so switching means giving up the specialty-targeting guarantee they are paying for.
What limits this company?
Adding or re-confirming a doctor's profile requires a separate manual check against that doctor's home state medical board. There are 50 state boards, each with its own paperwork formats and review steps that cannot be automated away. That manual process is the ceiling — it caps how fast the verified physician count can grow and how quickly the network can recover if doctors leave.
What does this company depend on?
The company cannot operate without access to all 50 state medical board licensing databases, the National Provider Identifier database, and HIPAA-compliant cloud infrastructure to run its telehealth services. It also relies on pharmaceutical companies continuing to spend money on campaigns that target doctors professionally rather than consumers directly.
Who depends on this company?
Pharmaceutical sales teams use it to reach specific types of doctors — cardiologists, oncologists, and others — for drug launches and clinical trial recruitment; without it, they lose the ability to verify they are actually reaching practicing licensed specialists. Hospital systems running Amion would face disruptions to on-call scheduling coordination. Doctors who see patients through Dialer Video would need to find another HIPAA-compliant telehealth platform.
How does this company scale?
Once a doctor is verified and in the system, serving that doctor with messaging tools or showing their profile to an advertiser costs very little extra. The communication routing infrastructure also scales cheaply once built. What does not scale easily is the credential verification step itself — the 50-state manual review process remains a fixed human-labor bottleneck no matter how large the network gets.
What external forces can significantly affect this company?
State medical boards are digitizing their records, which could make verification easier but could also close the open query interfaces the company currently uses. Federal telehealth reimbursement policy shapes whether doctors adopt virtual care tools at all — a policy reversal could reduce physician engagement with Dialer Video. If pharmaceutical companies shift their marketing budgets toward direct-to-consumer advertising instead of targeting doctors, the core advertising revenue shrinks.
Where is this company structurally vulnerable?
If a significant number of state medical boards cut off outside access to their licensing databases — through new privacy laws, closed digital systems, or changed access rules — the verification pipeline loses its core data source. Fewer doctors get verified, the HIPAA-compliant audience shrinks, and pharmaceutical advertisers can no longer trust that their campaigns are reaching the right licensed specialists. The revenue model depends entirely on that guarantee.
Sign in to view price data.
Sign inStructural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph